THE US Food and Drug Administration has issued new guidance on the development of "generic abuse-deterrent opioids" as part of the ongoing battle against the US opioid crisis.
The FDA has so far approved ten opioids with abuse-deterrent formulations (ADF) intended to make crushing a tablet to snort or dissolving a capsule to inject, more difficult or less rewarding.
However the uptake of the new products has been slow, with key factors including price because the anti-abuse formulations are currently only available as brand-name products.
The new guidance aims to help speed the development of generic versions of ADF opioids.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 17